Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it, while both treatments ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...